Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...

SAN FRANCISCO -- Most patients with HIV who received two broadly neutralizing antibodies (bNAbs) after pausing antiretroviral ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

The presence of anti-CD4 autoantibodies in treatment-naive patients with advanced HIV was associated with a decreased rate of CD4 reconstitution following ART initiation.

A survey of HIV health care providers in the US revealed the various approaches that providers took for prescribing ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...

HIV incidence in sub-Saharan Africa has declined substantially, according to both UNAIDS estimates and empirical data pulled ...